The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management

Area of Science:

• Microbiology
• Endocrinology
• Pharmacology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are key treatments for type 2 diabetes mellitus (T2DM) and obesity.
• The gut microbiome's role in metabolic health is increasingly recognized.
• Limited research exists on the interaction between GLP-1 RAs and the gut microbiome.

Purpose of the Study:

• To explore potential interactions between the gut microbiome and GLP-1 RA therapy.
• To review the current literature on GLP-1 RAs, microbiome, body weight, diet, and gastrointestinal symptoms.
• To propose future research directions for understanding this interplay.

Main Methods:

• Narrative review of existing scientific literature.
• Focus on potential relationships and proposed causal links.
• Identification of research gaps, particularly regarding diet's role.

Main Results:

• Evidence suggests GLP-1 RA-induced changes in diet, behavior, and weight loss are primary drivers of observed microbiome alterations.
• Significant gaps exist in understanding how diet mediates or confounds the effects of GLP-1 RAs on the gut microbiome.
• Current literature provides limited direct evidence on microbiome changes specifically due to GLP-1 RA mechanisms.

Conclusions:

• GLP-1 RA effects on the gut microbiome appear secondary to treatment-induced behavioral and physiological changes.
• Diet plays a crucial, yet understudied, role in the GLP-1 RA-microbiome axis.
• Future studies should investigate the direct and indirect effects of GLP-1 RAs on the gut microbiome, considering dietary influences.